Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenue: Product, net
- 7,246.70
- 7,987.80
- 8,846.90
- 10,692.20
- 11,379.80
- Revenue - Line of Business (LOBR)
- Revenue: Anti-CD20 Therapeutic Programs
- 1,689.60
- 1,700.50
- 1,659.00
- 1,977.80
- 2,290.40
- Revenue - Line of Business (LOBR)
- Revenue: Contract manufacturing, royalty and other revenue
- 899.30
- 485.10
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Fumarate: Tecfidera: Total
- 1,012.50
- 1,443.90
- 1,951.90
- 3,841.10
- 4,432.70
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Fumarate: Vumerity: Total
- 576.30
- 553.40
- 410.40
- 64.30
- 5.50
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Fumarate: Total
- 1,588.80
- 1,997.30
- 2,362.30
- 3,905.40
- 4,438.20
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Avonex: Total
- 811.00
- 973.50
- 1,208.70
- 1,491.90
- 1,666.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Plegridy: Total
- 294.70
- 331.90
- 357.40
- 385.60
- 436.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Interferon: Total
- 1,105.70
- 1,305.40
- 1,566.10
- 1,877.50
- 2,101.80
- Revenue - Line of Business (LOBR)
- Revenue: Product: Biosimilars: Benepali: Total
- 438.80
- 441.00
- 498.30
- 481.60
- 486.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Fampyra: Total
- 90.50
- 96.60
- 105.20
- 103.10
- 97.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Biosimilars: Flixabi: Total
- 77.40
- 81.30
- 99.40
- 97.90
- 68.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Tysabri: Total
- 1,876.90
- 2,030.90
- 2,063.10
- 1,946.10
- 1,892.20
- Revenue - Line of Business (LOBR)
- Revenue: RITUXAN/GAZYVA/LUNSUMIO revenue
- 409.40
- 547.00
- 666.80
- 1,132.40
- 1,603.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Other: Total
- 11.80
- 13.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Product: Biosimilars: BYOOVIZ: Total
- 31.70
- 4.30
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Other revenue from anti-CD20 therapeutic programs
- 14.00
- 17.20
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Product: Multiple Sclerosis: Total
- 4,661.90
- 5,430.20
- 6,096.70
- 7,832.10
- 8,529.30
- Revenue - Line of Business (LOBR)
- Revenue: Product: Biosimilars: Imraldi: Total
- 222.10
- 224.50
- 233.40
- 216.30
- 184.00
- Revenue - Line of Business (LOBR)
- Revenue: Ocrevus Royalties
- 1,266.20
- 1,136.30
- 991.70
- 845.40
- 688.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Biosimilars: Total
- 770.00
- 751.10
- 831.10
- 795.80
- 738.00
- Revenue - Line of Business (LOBR)
- Revenue: Product: Spinal Muscular Atrophy: Spinraza: Total
- 1,741.20
- 1,793.50
- 1,905.10
- 2,052.10
- 2,097.00
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Tecfidera: United States
- 263.10
- 417.70
- 680.60
- 2,677.70
- 3,306.50
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Tecfidera: Rest of world
- 749.40
- 1,026.20
- 1,271.30
- 1,163.40
- 1,126.20
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Vumerity: United States
- 512.10
- 521.30
- 408.90
- 64.30
- 5.50
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Vumerity: Rest of World
- 64.20
- 32.10
- 1.50
- --
- 0.00
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Fumarate: United States
- 775.20
- 939.00
- 1,089.50
- 2,742.00
- 3,312.00
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Fumarate: Rest of World
- 813.60
- 1,058.30
- 1,272.80
- 1,163.40
- 1,126.20
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Avonex: Rest of world
- 274.30
- 324.30
- 378.50
- 408.50
- 463.80
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Avonex: United States
- 536.70
- 649.20
- 830.20
- 1,083.40
- 1,202.10
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Plegridy: United States
- 126.20
- 148.40
- 152.90
- 190.10
- 224.50
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Plegridy: Rest of world
- 168.50
- 183.50
- 204.50
- 195.50
- 211.40
- Revenue - Geographic (GEOR)
- Revenue: Product: Biosimilars: Rest of World
- 740.80
- 746.80
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Biosimilars: United States
- 29.20
- 4.30
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis (MS): Rest of World
- 2,225.90
- 2,570.20
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Biosimilars: BYOOVIZ: Rest of World
- 2.50
- --
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Biosimilars: BYOOVIZ: United States
- 29.20
- 4.30
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Biosimilars: Imraldi: Rest of World
- 222.10
- 224.50
- 233.40
- 216.30
- 184.00
- Revenue - Geographic (GEOR)
- Revenue: Product: Spinal Muscular Atrophy: Spinraza: Rest of World
- 1,130.70
- 1,193.30
- 1,317.20
- 1,264.30
- 1,163.60
- Revenue - Geographic (GEOR)
- Revenue: Product: Spinal Muscular Atrophy: Spinraza: United States
- 610.50
- 600.20
- 587.90
- 787.80
- 933.40
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Interferon: Rest of world
- 442.80
- 507.80
- 583.00
- 604.00
- 675.20
- Revenue - Geographic (GEOR)
- Revenue: Product: Biosimilars: Benepali: Rest of World
- 438.80
- 441.00
- 498.30
- 481.60
- 486.20
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Interferon: United States
- 662.90
- 797.60
- 983.10
- 1,273.50
- 1,426.60
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis (MS): United States
- 2,436.00
- 2,860.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Rest of world
- 4,105.30
- 4,518.50
- 5,041.20
- 4,792.10
- 4,666.00
- Revenue - Geographic (GEOR)
- Revenue: Product: United States
- 3,141.40
- 3,469.30
- 3,805.70
- 5,900.10
- 6,713.80
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Tysabri: United States
- 997.90
- 1,123.40
- 1,142.20
- 1,096.80
- 1,041.80
- Revenue - Geographic (GEOR)
- Revenue: Product: Multiple Sclerosis: Tysabri: Rest of world
- 879.00
- 907.50
- 920.90
- 849.30
- 850.40
- Revenue - Geographic (GEOR)
- Revenue: Product: Other: Rest of World
- 7.80
- 8.20
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Product: Other: United States
- 4.00
- 4.80
- --
- --
- --